Innovative Collaborations Nicox actively pursues international partnerships, exemplified by its recent licensing agreement with Glaukos on NCX 1728, signaling opportunities for joint development and licensing deals with other ophthalmic firms seeking cutting-edge nitric oxide therapies.
Pipeline Expansion The company's focus on advancing lead candidates like NCX 470 through Phase 3 trials and exploring new molecules in glaucoma and retinal diseases offers multiple touchpoints for partnering or supplying specialized research and development services.
Market Growth Potential With recent positive analyst upgrades and a growing global focus on ophthalmology, Nicox presents potential sales opportunities by providing ophthalmic products and technologies to eye care providers seeking innovative treatments for conditions such as glaucoma and retinal disorders.
Niche Focus on Ophthalmology Specializing exclusively in ophthalmic R&D, Nicox's tailored portfolio targeting eye health opens doors for partnerships with healthcare companies, distributors, and OEMs looking to expand into or strengthen their ophthalmic product offerings.
Financial and Product Innovation Though currently under $10M revenue, Nicox’s significant funding and pipeline efforts suggest a readiness to support growth initiatives, presenting opportunities for investors, suppliers, and service providers aligned with innovative biotech advancements in ophthalmology.
$100M$250M
$10B
$25M$50M
$10B
$50M$100MNicox uses 8 technology products and services including Cloudflare, Open Graph, MySQL, and more. Explore Nicox's tech stack below.
| Nicox Email Formats | Percentage |
| Last@nicox.com | 54% |
| FLast@nicox.com | 19% |
| First.Last@nicox.com | 19% |
| First@nicox.com | 8% |
Pharmaceutical ManufacturingFrance11-50 Employees
Nicox is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world. Our global growth strategy is focused on outstanding international collaborations and on our proprietary programs including those from our nitric oxide-donating research platform. For more information please visit www.nicox.com
Company Overview
Funding & FinancialsNicox has raised a total of $54M of funding over 2 rounds. Their latest funding round was raised on Jan 25, 2019 in the amount of $23Mas a bond financing.
Nicox's revenue is estimated to be in the range of $10M$25M
Funding & FinancialsNicox has raised a total of $54M of funding over 2 rounds. Their latest funding round was raised on Jan 25, 2019 in the amount of $23Mas a bond financing.
Nicox's revenue is estimated to be in the range of $10M$25M
1-888-653-2347 
support@leadiq.com